Business Wire

GA-ADVA

5.10.2021 09:02:07 CEST | Business Wire | Press release

Share
ADVA protects critical network infrastructure with new end-to-end assured PNT solution

ADVA (FSE: ADV) today announced that it has responded to calls from the US Department of Homeland Security (DHS) and National Institute of Standards and Technology (NIST) to protect critical infrastructure from the growing danger of GNSS vulnerabilities and cyber threats to positioning, navigation and timing (PNT) services with the launch of its aPNT+™ platform . This scalable solution meets all the latest guidelines for resilient PNT and is the industry’s most complete offering. It provides end-to-end control and timing network visibility for the most robust protection available against the catastrophic risks that PNT disruption poses to national security and essential assets such as power grids.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005061/en/

“Cyber threats are at an all-time high. At the same time, the infrastructure that our economies and lives depend on has never been more reliant on weak and highly vulnerable satellite signals. That’s why the US DHS and NIST are driving for PNT services to be more resilient and for network operators to implement strategies to counteract the vulnerabilities of GPS and other GNSS systems, including in-network PTP timing feeds. Our trusted aPNT+ platform is the definitive response. Being open and scalable, it offers an end-to-end range of cost-effective solutions and the industry’s most comprehensive features for augmented resilience, robustness and cybersecurity,” said Gil Biran, general manager, Oscilloquartz, ADVA. “For industries and governments, timing is now a critical service in need of urgent protection. Our aPNT+ platform will be the cornerstone of the most effective defense in depth strategies.”

Governments worldwide have issued guidelines to protect businesses and society from disruption to PNT services, including US Executive Order 13905, which was followed by the DHS Resilient PNT Conformance Framework and NIST Cybersecurity Framework for PNT Profile. The guidelines urge operators to swiftly implement technologies and measures to safeguard vital infrastructure. Based on these, ADVA has integrated an intelligent and scalable aPNT platform into its product portfolio. Even without GPS or GNSS timing, the solution provides an intelligent, end-to-end self-recovery system designed around a threefold framework. Integrating sophisticated multi-layer detection, multi-source backup and multi-level fault-tolerant mitigation, it delivers the highest levels of resilience, robustness and cybersecurity. This is a new standard for assured PNT services, integrating not only the DHS framework’s four levels of PNT resilience but also providing enhanced level four resilience, the highest level for trusted PNT services assurance.

“Our aPNT+ platform will be invaluable for any critical infrastructure with a crucial dependence on PNT services. With our wide-ranging product portfolio, it offers all the building blocks to create an end-to-end solution, including advanced cesium clocks, our extensive family of PTP grandmasters from core to miniature, and our innovative sync assurance application,” said Nino De Falcis, senior director, business development, Oscilloquartz, ADVA. “From transportation to national defense, from energy to finance, today’s industries need to take action against the enormous risk to lives and livelihoods that reliance on PNT represents. Now there’s a new trusted way to prevent, respond and recover PNT services against disruption with our comprehensive aPNT+ solution.”

Further details on ADVA’s aPNT+ platform can be found in this guide: https://adva.li/apnt-sync-guide .

Supporting slides can be viewed here: https://adva.li/apnt-slides .


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye